This company profiles millions of cell-cell interactions at the single-cell level to functionally screen for therapeutic agents. They combine ultrafast interaction mapping with proprietary AI models to identify novel targets for drug development. This approach accelerates the creation of safer and more effective drugs for cancer and autoimmune diseases.
Funding
$13M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective immunotherapies for cancer is challenging due to the difficulty in identifying rare and specific therapeutic targets within the vast complexity of the immune system. Traditional methods lack the throughput and accuracy needed to functionally profile millions of immune cells simultaneously, hindering the discovery of novel targets.
Solution
Shennon Biotechnologies offers a proprietary ultra-high throughput single-cell platform designed to functionally profile millions of immune cells concurrently, enabling the identification of rare therapeutic targets. This platform addresses the bottleneck in immunotherapy development by providing unprecedented throughput and accuracy in analyzing immune cell function. By functionally profiling immune cells and their cognate antigens, Shennon Biotechnologies facilitates the development of more targeted and effective cell therapies, particularly for solid tumors and autoimmune diseases. The platform's capabilities extend to analyzing, understanding, and manipulating massive numbers of cells at the single-cell level, accelerating the discovery of novel immunotherapies.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel immunotherapies and cell therapies for cancer and autoimmune diseases.
Features
- Ultra-high throughput single-cell functional profiling of millions of immune cells
- Identification of rare and difficult-to-find therapeutic targets
- Functional profiling of immune cells and their cognate antigens
- Development of targeted cell therapies for solid tumors and autoimmune diseases
- Capabilities for analyzing, understanding, and manipulating cells at the single-cell level